Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -99843.01% is 50% above its 2-year average of -199868.92%, near the high end of its 2-year range (-832900.00%–-16379.17%).
61.73% above its 12-month average of -260877.89%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2024 (2024-12-31): -832900.00%.
EBITDA MARGIN
-99843.01%
EBITDA MARGIN AVG TTM
-260877.89%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+61.73%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Fractyl Health, Inc.
Market Cap
$58.24M
EBITDA Margin
-99843.01%
TTM Avg
-260877.89%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$58.99M
EBITDA Margin
-3226.05%
TTM Avg
-3226.05%
3Y Avg
-3226.05%
5Y Avg
-3226.05%
Market Cap
$55.21M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$59.91M
EBITDA Margin
-753.96%
TTM Avg
-753.96%
3Y Avg
-753.96%
5Y Avg
-753.96%
Market Cap
$60.32M
EBITDA Margin
-89640.62%
TTM Avg
-44862.17%
3Y Avg
-44862.17%
5Y Avg
-44862.17%
Market Cap
$60.49M
EBITDA Margin
-92.40%
TTM Avg
-510.72%
3Y Avg
-510.72%
5Y Avg
-510.72%
Market Cap
$60.81M
EBITDA Margin
-270.28%
TTM Avg
-442.93%
3Y Avg
-1031.00%
5Y Avg
-861.19%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fractyl Health, Inc. (GUTS) | $58.24M | -99843.01% | -260877.89% | N/A | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.99M | -3226.05% | -3226.05% | -3226.05% | -3226.05% |
| Boundless Bio, Inc. (BOLD)vs › | $57.54M | N/A | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $55.21M | N/A | N/A | N/A | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.78M | N/A | N/A | N/A | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $59.91M | -753.96% | -753.96% | -753.96% | -753.96% |
| Connect Biopharma Holdings Limited (CNTB)vs › | $60.32M | -89640.62% | -44862.17% | -44862.17% | -44862.17% |
| Xilio Therapeutics, Inc. (XLO)vs › | $60.49M | -92.40% | -510.72% | -510.72% | -510.72% |
| Adicet Bio, Inc. (ACET)vs › | $60.81M | -270.28% | -442.93% | -1031.00% | -861.19% |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.12M | -16170.91% | -8243.87% | -8243.87% | -8243.87% |
Gross Margin
0.0%
EBITDA Margin
-99843.0%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2024-12-31 | -832900.00% |
| 2024-09-30 | -168464.29% |
| 2024-06-30 | -53006.98% |
| 2024-03-31 | -65118.18% |
| 2023-12-31 | -184900.00% |
| 2023-09-30 | -38302.78% |
| 2023-06-30 | -16379.17% |
| 2023-03-31 | -239880.00% |
